Table 1.

CHK1 inhibitor concentrations required to sensitize AML lines to CPX-351.

Inhibitor	Concentration to sensitize to CPX-351 in vitro	Mean plasma concentration 24 h after administration at MTD*	Reference
MK-8776	300–600 nM (Figs 2 and 5a)	30 ng/ml = 80 nM	40, 48
Rabusertib	300 nM (Figs 3b and S4a)	1000 ng/ml = 2.5 µM	49
Prexasertib	3 nM (Figs 3c and 4b)	15 ng/ml = 41 nM	42

*Indicates the mean plasma concentration 24 h after the administration of the indicated inhibitor at the maximum tolerated dose (MTD) as a single agent except in the case of MK-8776, where the MTD with cytarabine is similar to that as a single agent as indicated in the cited references.